Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs

Sun-Young Kong, MD, PhD, Xian-Feng Li, Sabikun Nahar, Weihua Song, MD, Michel de Weers, Paul W.H.I. Parren, Paul Richardson, M.D., Ph.D., Nikhil C. Munshi, MD, Kenneth C. Anderson, Yu-Tzu Tai, PhD

Blood (2010) 116 (21): 3013.

https://doi.org/10.1182/blood.V116.21.3013.3013

Published: 2010

Journal Articles

Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol

Blood (2010) 116 (21): 906.

https://doi.org/10.1182/blood.V116.21.906.906

Published: 2010

Journal Articles

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene Ghobrial, MD, Tiffany Poon, BS, Meghan Rourke, Stacey Chuma, BSN, Janet Kunsman, NP, Ranjit Banwait, Amy Sam, Diane Warren, Kenneth C. Anderson, Paul Richardson, M.D., Ph.D., Steven P. Treon, MD, PhD, Jeffrey Matous, MD

Blood (2010) 116 (21): 3952.

https://doi.org/10.1182/blood.V116.21.3952.3952

Published: 2010

Journal Articles

Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation

Sun-Young Kong, MD, PhD, Sabikun Nahar, Xian-Feng Li, Weihua Song, MD, Yiguo Hu, Umesh Muchhal, John Desjarlais, Paul Richardson, M.D., Ph.D., Nikhil C. Munshi, MD, Kenneth C. Anderson, Yu-Tzu Tai, PhD

Blood (2010) 116 (21): 4064.

https://doi.org/10.1182/blood.V116.21.4064.4064

Published: 2010

Journal Articles

Lack of Response to Vaccination in MGUS and Stable Myeloma.

Rao H Prabhala, PhD, Yvonne A Efebera, MD, Saem Lee, Andrew J Han, Dheeraj Pelluru, Puru Nanjappa, MS, Samir Amin, Christine Pai, Irene Ghobrial, M.D., Robert L Schlossman, M.D., Ph.D., Jacob Laubach, Mariateresa Fulciniti, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2009) 114 (22): 1852.

https://doi.org/10.1182/blood.V114.22.1852.1852

Published: 2009

Journal Articles

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.

Blood (2009) 114 (22): 1869.

https://doi.org/10.1182/blood.V114.22.1869.1869

Published: 2009

Journal Articles

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

Noopur Raje, MD., Paul Richardson, M.D., Parameswaran N Hari, MD, Anuj Mahindra, Sarah Kaster, BS, Christine Connolly, Linda Rivera, Gaurav Chetri, Sarah Dean, Paulette Jacobs, Ayman Saad, MD, Jacob Laubach, Irene M. Ghobrial, M.D., Robert L Schlossman, M.D., Ph.D., Jennifer Adams, Wendy Makrides, Edie Weller, PhD, Nikhil Munshi, M.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3856.

https://doi.org/10.1182/blood.V114.22.3856.3856

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Swaminathan Padmanabhan, Ashraf Z. Badros, MD, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Jeffrey Matous

Blood (2009) 114 (22): 3752.

https://doi.org/10.1182/blood.V114.22.3752.3752

Published: 2009

Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, M.D, Craig Hofmeister, MD, Andrzej Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Susan L. Kelly, MD, Saskia Neuteboom, PhD, Gillian F Cropp, MSc, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 431.

https://doi.org/10.1182/blood.V114.22.431.431

Published: 2009

Journal Articles

Evolution of Genomic Changes and Their Significance in Myeloma.

Masood A Shammas, PhD, Herve Loiseau, Cheng Li, Ph.D, Leutz Buon, Samir B Amin, MBBS, Parantu Shah, PhD, King Ben, MD, Mariateresa Fulciniti, yu-Tzu Thai, PhD, Paul Richardson, M.D., Ph.D., Stephane Minvielle, Ph.D, Kenneth C. Anderson, Nikhil C. Munshi

Blood (2009) 114 (22): 605.

https://doi.org/10.1182/blood.V114.22.605.605

Published: 2009

Journal Articles

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Yu-Tzu Tai, Ph.D., Michel de Weers, Ph.D., Xian-Feng Li, MS, Weihua Song, MD, Sabikun Nahar, B.S., Joost M Bakker, Tom Vink, Daniëlle Jacobs, Lukas Oomen, Wim K Bleeker, Nikhil C. Munshi, MD, Jan G. J. van de Winkel, PhD, Paul W. H. I. Parren, PhD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 608.

https://doi.org/10.1182/blood.V114.22.608.608

Published: 2009

Journal Articles

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Umesh Muchhal, Ph.D., Xian-Feng Li, MS, Sabikun Nahar, B.S., Weihua Song, MD, Holly Horton, Ph.D, Hanh Nguyen, Sher Karki, John Desjarlais, Nikhil C. Munshi, MD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 609.

https://doi.org/10.1182/blood.V114.22.609.609

Published: 2009

Journal Articles

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Blood (2009) 114 (22): 587.

https://doi.org/10.1182/blood.V114.22.587.587

Published: 2009

Journal Articles

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

Yu-Tzu Tai, Ph.D., Kihyun Kim, M.D., Xian-Feng Li, M.S., Mariateresa Fulciniti, Ph.D., Weihua Song, M.D., Sabikun Nahar, B.S., Peter Burger, B.S., Mathew J. Rumizen, Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D, Teru Hideshima, M.D., Ph.D., Robert L Schlossman, M.D., Ph.D., Nikhil C. Munshi, Paul Richardson, M.D., Ph.D., Ann Clark, Ph.D., Janet Ogden, Ph.D., Goutopoulos Andreas, Ph.D., Luca Rastelli, Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3848.

https://doi.org/10.1182/blood.V114.22.3848.3848

Published: 2009

Journal Articles

Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.

Paul Richardson, M.D., Marcie Tomblyn, MD, MS, Nancy Kernan, M.D., Joel A. Brochstein, MD, Shin Mineishi, MD, Amanda Termuhlen, MD, Sally Arai, MD, Stephan A. Grupp, MD, PhD, Eva Guinan, M.D., Paul L. Martin, MD, PhD, Selim Corbacioglu, MD, Ernst Holler, M.D., Ralph D'Agostino, Ph.D., Joseph Massaro, Ph.D., Alison L. Hannah, MD, Massimo Iacobelli, M.D., Robert J Soiffer, MD

Blood (2009) 114 (22): 654.

https://doi.org/10.1182/blood.V114.22.654.654

Published: 2009

Journal Articles

Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.

Blood (2009) 114 (22): 783.

https://doi.org/10.1182/blood.V114.22.783.783

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

Irene M. Ghobrial, M.D., Ravi Vij, MD, Nikhil C. Munshi, Robert L Schlossman, M.D., Ph.D., Jacob Laubach, Erica L. Campagnaro, MD, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, NP, Akari M. Dollard, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D.

Blood (2009) 114 (22): 748.

https://doi.org/10.1182/blood.V114.22.748.748

Published: 2009

Journal Articles

Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism.

Melissa G Ooi, M.D., Paul Dowling, Ph.D, Paul Richardson, M.D., Constantine S. Mitsiades, M.D., Ph.D, Martin Clynes, Ph.D, Kenneth C. Anderson, Peter O'Gorman, M.D.

Blood (2009) 114 (22): 1805.

https://doi.org/10.1182/blood.V114.22.1805.1805

Published: 2009

Journal Articles

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Melissa G Ooi, M.D., Robert O'Connor, Ph.D, Jana Jakubikova, Ph.D, Justine Meiller, Diploma, in, Biochemistry, Degre, Steffen Klippel, Ph.D, Jake Delmore, Efstathios Kastritis, M.D, Douglas McMillin, Ph.D, Martin Clynes, Ph.D, Paul Richardson, M.D., Constantine S. Mitsiades, M.D., Ph.D, Peter O'Gorman, M.D., Kenneth C. Anderson, M.D.

Blood (2009) 114 (22): 1729.

https://doi.org/10.1182/blood.V114.22.1729.1729

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Fangxin Hong, PhD, Swaminathan Padmanabhan, MD, Ashraf Z. Badros, MD, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Edie Weller, PhD, Jeffrey Matous

Blood (2009) 114 (22): 2727.

https://doi.org/10.1182/blood.V114.22.2727.2727

Published: 2009

NARROW

Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs

Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation

Lack of Response to Vaccination in MGUS and Stable Myeloma.

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Evolution of Genomic Changes and Their Significance in Myeloma.

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.

Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism.

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only